ASXL1 and chronic myelomonocytic leukemia: It has been shown by several investigators that in CMML patients mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%) and the oncogenic RAS pathway (~30%) are frequent [20].